

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)



(10) International Publication Number
WO 2022/238901 A1

(51) International Patent Classification:

G01N 33/569 (2006.01) G01N 33/574 (2006.01)
A61K 39/00 (2006.01) G01N 33/68 (2006.01)

(21) International Application Number:

PCT/IB2022/054342

(22) International Filing Date:

10 May 2022 (10.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/186,872 11 May 2021 (11.05.2021) US

(71) Applicants: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US). LEGEND BIOTECH USA INC. [US/US]; 10
Knightsbridge Road., NJ, Piscataway, New Jersey 08854
(US).

(72) Inventors: AKRAM, Muhammad S.; 2101 Cottontail
Lane, Somerset, New Jersey 08873 (US). DE BRAGAN-
CA, Kevin C.; 920 US Route 202, Raritan, New Jersey
08869 (US). GOLDBERG, Jenna; 920 US Route 202,
Raritan, New Jersey 08869 (US). JACKSON, Carolyn
Chang; 920 US Route 202, Raritan, New Jersey 08869
(US). LEE, Erin C.; 1125 Trenton-Harbourton Road, Ti-
tusville, New Jersey 08560 (US). LENDVAI, Nikolettai;
920 US Route 202, Raritan, New Jersey 08869 (US). DE

MONDELO, Maria Marquez; 920 US Route 202, Raritan,
New Jersey 08869 (US). OLYSLAGER, Yunsu; Turnhout-
seweg 30, B2340 Beerse (BE). QIU, Jun; 2101 Cottontail
Lane, Somerset, New Jersey 08873 (US). UBANI, Enrique
Zudaire; 1400 McKean Road, Spring House, Pennsylvania
19477 (US). XU, Jean; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US).

(74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY




FIG. 1

(57) Abstract: The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*